

Rituximab Unspecified Plan of Treatment for GPA/MPA

Referral Status:	MRN:
<input type="checkbox"/> New referral	<input type="checkbox"/> Order change
<input type="checkbox"/> Order change	<input type="checkbox"/> Order change
Patient preferred clinic:	

PATIENT DEMOGRAPHICS:

Date of Referral:	Patient's Phone:
Patient Name:	Address:
Date of Birth:	City, State, Zip:
Height in inches:	Weight: LB or KG
Gender:	Allergies:
	See list
	NKDA

DIAGNOSIS: (PLEASE COMPLETE 2ND AND 3RD DIGITS TO COMPLETE ICD 10 FOR BILLING)

<input type="checkbox"/> M31.30 - Granulomatosis with Polyangiitis (GPA/Wegener's Granulomatosis)
<input type="checkbox"/> M31.7 - Microscopic Polyangiitis (MPA)
<input type="checkbox"/> - Other:

REQUESTED DOCUMENTATION: PREVIOUS ADMINISTRATION: HAS THIS PATIENT TAKEN THIS MEDICATION BEFORE?

1	Insurance information	IF NO:	IF YES:
2	Most recent History & Physical	PLEASE STATE	LAST INFUSION DATE:
3	Most recent labs including CBC with diff	REQUIRED WASHOUT	NEXT INFUSION DATE:
4	Full medication list / Tried and failed therapies	FROM PREVIOUS	
5	REQUIRED: Hepatitis B Panel for new start patients	THERAPY:	
			IF ORDER CHANGE:
			Continue current order until insurance approved

MEDICATION ORDERS:

NOTE: Patient may be ineligible to receive rituximab if receiving antibiotics for active infectious process, antifungal therapy, active fever and/or suspected infection, newly diagnosed cardiac arrhythmias, severe abdominal pain or vomiting, and/or surgery.

PREMEDICATION TO BE ADMINISTERED 30 MINUTES PRIOR TO ADMINISTRATION AS SELECTED

*Per FDA labeling, Acetaminophen PO, Diphenhydramine IVP, and Methylprednisolone IVP is suggested prior to infusion

IV	Diphenhydramine	25mg	50mg		PO	Acetaminophen	325mg	500mg	650mg	1000mg
	Methylprednisolone	40mg	125mg	Other:		Famotidine	20mg	40mg		
	Famotidine	20mg	40mg			Diphenhydramine	25mg	50mg		
	Other:					Fexofenadine	60mg	180mg		
						Cetirizine	10mg			
				Loratadine	10mg					
				Other:						

DRUG PRODUCT:

- Rituxan
- Ruxience
- Truxima
- Riabni

Biosimilar may be used according to payer guidelines
If selected, prescriber must sign substitution permitted line

INDUCTION DOSE:

375mg/m2 per 250 - 500ml NS IV to infuse per step protocol once weekly x 4 weeks

Other: _____

SPECIAL/LAB ORDERS:

MAINTENANCE DOSE: (begin _____ months after last induction dose)

500mg/500ml NS IV to infuse per step protocol

1000mg/500ml NS IV to infuse per step protocol

Other: _____

MAINTENANCE FREQUENCY:

Infuse dose every 4 months 6 months

Other: _____

Refills x 12 months unless noted otherwise here:

Prescriber to monitor patient for symptoms of HBV infection and reactivation as clinically appropriate.

LINE USE/CARE ORDERS: ADVERSE REACTION & ANAPHYLAXIS ORDERS:

- Start PIV/Access CVC
- Flush device per facility standard flushing procedure

Administer acute infusion and anaphylaxis medications per Palmetto Infusion standing adverse reaction orders, which can be found at our website or scan here.



PRESCRIBER INFORMATION:

PROVIDER NAME:	PHONE:
ADDRESS:	FAX:
CITY, STATE, ZIP:	NPI:

PRESCRIBER SIGNATURE: (No stamp signatures) DATE

Dispense as written/Brand medically necessary	Substitution permitted